Recursos COVID-19

Information for clinicians on mechanism of action for Molnupiravir, contraindications & indications, general dosage guidelines

Information for clinicians on mechanism of action for Paxlovid, contraindications & indications, general dosage guidelines.

Brief overview of the Test-to-Treat activity, answers key questions on purpose and target population

Information on purpose and use of self-tests in various environments.

Check out our OCC Job Aid Builder Tool for more free content to make your own job aid. Topics include respiratory care, emergency algorithms, critical care medications, procedures with more topics and more languages coming soon.

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Fiche d'information de deux pages conçue pour les patients qui prennent du molnupiravir. Il est destiné à être imprimé recto-verso et plié en deux.

Hoja de información de dos páginas diseñada para pacientes que están tomando molnupiravir. Está destinado a ser impreso a doble cara y doblado por la mitad.

Two-page information sheet designed for patients who are taking molnupiravir. It is intended to be printed double-sided and folded in half.

Two-page information sheet designed for patients who are taking Paxlovid. It is intended to be printed double-sided and folded in half

This slide deck covers topics such as triage, testing and clinical management of COVID-19, including treatment with oral antiviral therapy.
This facilitator guide accompanies the slide deck and includes a script for the facilitator to teach this topic.

This document provides answers to frequently asked questions about the COVID-19 Test to Treat strategy for clinicians, prescribers and health care teams.

This calculator allows users to estimate the number of courses of oral antivirals that might be required during a calendar period, based on infection rate inputs.

Guidelines on COVID-19 Test to Treat, by the Africa Centres for Disease Control and Prevention (Guidance to Africa Union Member States)

Cet algorithme et ce guide de mise en œuvre sont destinés à aider les cliniciens au point de service à initier un traitement antiviral oral pour la COVID-19. Sur la base des données, le nirmatrelvir/ritonavir (NMV/r) est l'agent préféré, suivi du molnupiravir.

Ces ressources ont été créées par les partenaires EpIC, RISE, STAR-UCSF.

Este algoritmo es para ayudar a los médicos en el punto de atención a iniciar el tratamiento con antivíricos por vía oral para el COVID-19. En función de los datos, nirmatrelvir/ritonavir (NMV/r) se prefiere, seguido de molnupiravir.

Estos recursos fueron creados por los colaboradores EpIC, RISE, STAR-UCSF.

Webinar 6: Oxygen therapies and delivery devices in COVID-19 - Where are we now? with Neill Adhikari, Rich Branson, Elisabeth Riviello, Sheila Myatra, and Arthur Kwizera.

Moderated by Tyler Law.

Webinar 5: Mental Health & Frontline Healthcare Workers with Brandon Kohrt, Khoa Duong, Diana Frymus, Laura Murray moderated by Kate Douglass

Here are some of the resources mentioned during the webinar:
WHO-UNICEF: Mental Health and Psychosocial Support (MHPSS) Minimum Service Package (MSP);
OCHA IASC: Mental Health and Psychosocial Support (MHPSS) Monitoring and Evaluation with Means of Verification
WHO UNICEF: Ensuring Quality in Psychological Support (EQUIP) Platform
WHO: World Mental Health Report 2022
IASC 4W's: Who is Where, When, doing What in Mental Health and Psychosocial Support

This algorithm and implementation guide are intended to help clinicians at the point of care initiate oral antiviral treatment for COVID-19. Based on efficacy data, nirmatrelvir/ritonavir (NMV/r) is the preferred agent, followed by molnupiravir.

These tools were created by USAID Implementing partners EpIC, RISE, STAR-UCSF.